// App-Quantinova.ai

2278 : DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) Effects on Patient-Reported Outcome (PRO) Measures in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Researchers

Presenter

  • Rakesh Popat

Principal Investigators

  • Sagar Lonial

  • Peter M. Voorhees

  • Simona Degli Esposti

  • Ira Gupta

  • Joanna Opalinska

  • Sandhya Sapra

  • Boris Gorsh

  • Zangdong He

  • David M Kleinman

  • Debra Schaumberg

  • Angely Loubert

  • Juliette Meunier

  • Antoine Regnault

  • Laurie Eliason

Medical Centers

  • University College London Hospitals NHS Trust, London, United Kingdom

  • Emory University, Winship Cancer Institute, Atlanta, GA

  • Levine Cancer Institute, Atrium Health, Charlotte, NC

  • NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London

  • GlaxoSmithKline, Upper Providence, PA

  • Wilmot Cancer Institute, University of Rochester, Rochester, NY

  • Department of Ophthalmology and Visual Sciences, University of Utah School of Medicine, Salt Lake City, Utah, United States

  • Modus Outcomes, Lyon, France

Locations

  • United Kingdom

  • United States

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • GSK2857916

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT03525678

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved